Sector News

AbbVie to buy US biotech firm Aliada for $1.4 Billion

November 1, 2024
Life sciences

US drugmaker AbbVie has signed an agreement to acquire biotechnology company Aliada Therapeutics, which develops therapies for central nervous system (CNS) diseases using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.

Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash. The transaction is expected to close in the fourth quarter of 2024, subject to regulatory approvals and other customary closing conditions.

Aliada’s lead investigational asset, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer’s disease.

The Boston, US-based company is advancing therapeutic candidates using its Modular Delivery (MODEL) platform, engineered for high-precision CNS drug delivery. The novel BBB-crossing technology targets transferrin and CD98 receptors (TfR and CD98) which are highly expressed in brain endothelial cells. By engineering highly optimized TfR or CD98 binders, this platform is designed to deliver different types of biological cargoes into the brain, including therapeutic antibodies and genetic medicines such as siRNA.

Roopal Thakkar, AbbVie’s executive vice president, research and development and chief scientific officer, said: “This acquisition immediately positions us to advance ALIA-1758, a potentially best-in-class disease-modifying therapy for Alzheimer’s disease. In addition, Aliada’s novel BBB-crossing technology strengthens our R&D capabilities to accelerate the development of next-generation therapies for neurological disorders and other diseases where enhanced delivery of therapeutics into the CNS is beneficial.”

Michael Ryan, chief medical officer at Aliada Therapeutics, added: “Many promising CNS-targeted therapies fail to reach late-stage trials due to their inability to cross the blood-brain barrier. Our MODEL platform addresses this challenge directly, efficiently delivering targeted drugs and potentially transforming how we treat neurological diseases.”

Source: chemanager-online.com

comments closed

Related News

December 14, 2024

With green light from European Commission, Novo Holdings’ proposed $16.5B Catalent buyout nears close

Life sciences

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have said they expect to close before year-end—just received a major vote of confidence from antitrust officials overseas.

December 14, 2024

EuroAPI vaults operating chief into CEO role as it embarks upon ‘new chapter’

Life sciences

With EuroAPI’s restructuring plan underway, the Sanofi spinoff has pulled a new CEO from within its ranks to guide the company’s next chapter. Drug ingredients specialist EuroAPI on Monday said it had accepted the resignations of Ludwig de Mot as CEO and Viviane Monges as chair of the manufacturer’s board.

December 14, 2024

Lonza plans to shed capsules business, simplify operating structure in push to become ‘pure-play’ CDMO

Life sciences

During an investor update Thursday, Lonza unveiled its “One Lonza” restructuring strategy, under which the company will reorganize its CDMO business, reshape its operating model, work to “elevate” manufacturing and engineering and expand its production footprint.

How can we help you?

We're easy to reach